SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
China Dasheng Biotechnology Company (CDBT) .
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
Overall SharesGrow Score: 28/100 with 0/7 criteria passed.
SharesGrow 7-Criteria Score
✗
HEALTH
0/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — CDBT
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.00
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-0.02
Book Value / Share$0.00
Revenue / Share$0.00
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2004 |
$0.00 |
$630.69K |
$-22.75K |
-3.6% |
| 2005 |
$0.00 |
$484.84K |
$-16.86K |
-3.5% |
| 2006 |
$-0.01 |
$0.00 |
$-68.45K |
- |
| 2007 |
$0.15 |
$16.29M |
$4.64M |
28.5% |
| 2021 |
$0.00 |
$0.00 |
$0.00 |
- |
| 2022 |
$-0.02 |
$0.00 |
$-967K |
- |
